Press Releases

 
Press Releases
Date Title and Summary View
Mar 20, 2015 SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. "EMPATHY-P showed that ...
Mar 17, 2015 SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD™ companion diagnostic test to prospectively identify patients with metastatic breast, ova...
Mar 5, 2015 SALT LAKE CITY, March 5, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc., (Nasdaq:MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers...
Mar 4, 2015 SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent dia...
Mar 2, 2015 SALT LAKE CITY, March 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetic Laboratories, is scheduled to present at the Barclays Global Healthcare Conference at 11:15 a.m. Eastern on March 11, 2015, at Loews Miami Beach Hotel in Miami Beach, Florida. The presentation will ...
Feb 24, 2015 SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of December 31, 2014, the Company has repurchased almost $1 billion of stock since the inception of the program in 201...
Feb 6, 2015 SALT LAKE CITY, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink Global Healthcare Conference at 1:00 p.m. Eastern on February 12, 2015, at the Waldorf Astoria in New York, New York. The presentation will be av...
Feb 3, 2015 SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously...
Feb 3, 2015 Revenues of $184.4 MillionAdjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk™ Hereditary Cancer Revenues of $85.1 MillionBRACAnalysis CDx™ Approved by the FDATumor BRACAnalysis CDx™ Granted European CE Marking ApprovalCompany Revises Fiscal Year 2015 Financial Guidance; Provides Fiscal 3Q15 Financial Guidance SALT ...
Jan 22, 2015 SALT LAKE CITY, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Johnathan M. Lancaster, M.D., Ph.D. has joined the Company as the vice president of Medical Affairs for Oncology, Myriad Genetic Laboratories, effective Feb. 9, 2015. In this new role, Dr. Lancaster will provide medical and scientific leadersh...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase